Printer Friendly

SUMMIT SUBMITS PMA APPLICATION TO FDA FOR TREATMENT OF MYOPIA

 WALTHAM, Mass., Oct. 12 /PRNewswire/ -- Summit Technology, Inc. (NASDAQ: BEAM) announced today that it has submitted to the Food and Drug Administration (FDA) its Premarket Approval Application (PMA) for the commercial sale of is OmniMed(TM) excimer laser system for the treatment of nearsightedness. Summit believes it is the only company in the field of laser refractive surgery to reach this goal.
 The treatment, known as Photorefractive Keratectomy (PRK), uses the excimer laser to gently reshape the cornea with the result being that most patients do not require the use of eyeglasses or contact lenses post-operatively. In the United States alone, there are approximately 60 million nearsighted people and the vast majority of them are potential candidates for Summit's excimer laser PRK procedure.
 This PMA application represents the culmination of over five years of United States clinical trials in which approximately 2,000 treatments have been performed using Summit's laser system. Concurrently, Summit's excimer laser system has been in commercial operation in many countries around the world and to date it is estimated that well over 60,000 procedures have been successfully performed using Summit's systems.
 The PMA document consists of over 14,000 pages of clinical data and supporting technical information which has been compiled by the Company's United States clinical investigators and its Regulatory and Clinical Affairs team.
 "The submission of this application is on of the most important milestones in Summit's development and it is result of uncountable hours, days, and years of work by our collaborative clinical researchers and our Regulatory Affairs team. I believe the data strongly supports our application to the FDA and ultimately will result in full approval our product for commercial use," states David F. Muller, Ph.D., president and chairman.
 Summit Technology, Inc. is a worldwide leader in the development, manufacture and sale of ophthalmic laser systems designed to correct common refractive vision disorders such as nearsightedness, farsightedness and astigmatism.
 -0- 10/12/93
 /CONTACT: Paula Rainville, investor relations for Summit Technology, 617-890-1234/
 (BEAM)


CO: Summit Technology, Inc. ST: Massachusetts IN: MTC SU:

CM-JL -- NE003 -- 0935 10/12/93 08:32 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 12, 1993
Words:351
Previous Article:AIR METHODS TO BENEFIT FROM CHANGES OUTLINED IN PRESIDENT CLINTON'S PROPOSED HEALTH CARE REFORM LEGISLATION
Next Article:DELOITTE & TOUCHE 1993 ANNUAL REPORT OFFERS ASSESSMENTS AND OPINIONS ON KEY BUSINESS ISSUES
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters